Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Moderna Stock Jumped Today

By Brian Orelli, PhD - Updated Mar 2, 2020 at 1:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's vaccine for the new coronavirus outbreak could help as the disease continues to spread.

What happened

Shares of Moderna (MRNA 0.70%) are up 14% at 1:01 p.m. EST on Monday, having been up as much as 18.6% today, likely because COVID-19, the illness caused by the new coronavirus, continues to spread globally.

There have been over 89,000 confirmed cases of the disease according to data tracked by Johns Hopkins University's Center for Systems Science and Engineering. While most (over 80,000) have been in mainland China, the number of cases outside that country continues to climb. A second death in the U.S. from the disease was reported Sunday night.

So what

Moderna has already created a vaccine, mRNA-1273, which the biotech has shipped to researchers at the National Institute of Allergy and Infectious Diseases. A clinical trial is scheduled to start this month, which will produce early initial results by August.

President Donald Trump was scheduled to meet with executives from drug companies today to discuss the situation. It isn't clear what Trump or Vice President Mike Pence, who is heading the U.S. government's response to COVID-19, can do to speed up the process. Drug development takes time.

People on the sidewalk wearing masks

Image source: Getty Images.

Now what

While mRNA-1273 offers an opportunity for Moderna to generate revenue quicker than it likely will with its pipeline of drugs, biotech investors should be cautious about penciling in too much future revenue into their valuation models. Other companies are also working on vaccines for COVID-19, and if multiple vaccines are equally effective, the opportunity for each company could be short-lived.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$144.27 (0.70%) $1.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.